Seminars in Oncology
Volume 35 , Pages S31-S38 , April 2008

Emerging Agents in the Treatment of Anthracycline- and Taxane-Refractory Metastatic Breast Cancer

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving?. Cancer. 2004;100:44–52
  3. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485–493
  4. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004;40:536–542
  5. Ahn JH, Kim SB, Kim TW, et al. Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci. 2004;19:547–553
  6. Donadio M, Ardine M, Berruti A, et al. Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes. Oncology. 2005;69:408–413
  7. Lin PC, Wang WS, Yang MH, et al. Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer. J Chin Med Assoc. 2006;69:304–309
  8. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743
  9. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792–799
  10. Dent S, Messersmith H, Trudeau M. Gemcitabine in the management of metastatic breast cancer: A systematic review. Breast Cancer Res Treat. 2007;[Epub ahead of print]
  11. Modi S, Currie VE, Seidman AD, et al. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer. 2005;6:55–60
  12. Rha SY, Moon YH, Jeung HC, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat. 2005;90:215–221
  13. Smorenburg CH, Bontenbal M, Seynaeve C, et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat. 2001;66:83–87
  14. Sánchez-Escribano Morcuende R, Alés-Martínez JE, Aramburo González PM. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens. Clin Transl Oncol. 2007;9:459–464
  15. Frasci G, D'Aiuto G, Comella P, et al. A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients. Oncology. 2002;62:25–32
  16. Martin M, Ruiz A, Muñoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: Final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007;8:219–225
  17. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 2001;92:2267–2272
  18. Ray-Coquard I, Biron P, Bachelot T, et al. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer. 1998;82:134–140
  19. Vassilomanolakis M, Koumakis G, Demiri M, et al. Vinorelbine and cisplatin for metastatic breast cancer: A salvage regimen in patients progressing after docetaxel and anthracycline treatment. Cancer Invest. 2003;21:497–504
  20. Carrick S, Ghersi D, Wilcken N, et al. Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2004;CD003374
  21. Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol. 1999;26(suppl 12):89–95
  22. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006;24:2786–2792
  23. Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: A phase II study. Ann Oncol. 2003;14:537–542
  24. Zelek L, Cottu P, Tubiana-Hulin M, et al. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol. 2002;20:2551–2558
  25. Petit T, Benider A, Yovine A, et al. Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer. Anticancer Drugs. 2006;17:337–343
  26. Delozier T, Guastalla JP, Yovine A, et al. A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. Anticancer Drugs. 2006;17:1067–1073
  27. Perez EA, Hillman DW, Mailliard JA, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol. 2004;22:2849–2855
  28. Frasci G, D'Aiuto G, Thomas R, et al. Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in anthracycline-paclitaxel-refractory breast cancer patients. Oncology. 2005;68:391–397
  29. O'Connor T, Rustum Y, Levine E, et al. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. Cancer Chemother Pharmacol. 2008;61:125–131
  30. Esteva FJ, Rivera E, Cristofanilli M, et al. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer. 2003;98:900–907
  31. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7:1429–1437
  32. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005;23:2726–2734
  33. Denduluri N, Lee JJ, Walshe J, et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs. 2007;25:63–67
  34. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007;25:3399–3406
  35. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007;25:3415–3420
  36. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407–3414
  37. Spielmann M, Martin M, Namer M, et al. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: An interim analysis. Clin Breast Cancer. 2001;2:47–51
  38. O'Shaughnessy JA, Clark RS, Blum JL, et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer. 2005;6:143–149
  39. Kruczynski A, Colpaert F, Tarayre JP, et al. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated vinca alkaloid. Cancer Chemother Pharmacol. 1998;41:437–447
  40. Lobert S, Ingram JW, Hill BT, et al. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol. 1998;53:908–915
  41. Bennouna J, Fumoleau P, Armand JP, et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol. 2003;14:630–637
  42. Campone M, Cortes-Funes H, Vorobiof D, et al. Vinflunine: A new active drug for second-line treatment of advanced breast cancer (Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy). Br J Cancer. 2006;95:1161–1166
  43. Dabydeen DA, Burnett JC, Bai R, et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol. 2006;70:1866–1875
  44. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4:1086–1095
  45. Zelek L, Yovine A, Brain E, et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer. 2006;94:1610–1614
  46. Foss F. Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006;33(suppl 3):S11–S16
  47. Turturro F. Denileukin diftitox: A biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007;7:11–17
  48. Solit DB, Basso AD, Olshen AB, et al. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 2003;63:2139–2144
  49. Zsebik B, Citri A, Isola J, et al. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett. 2006;104:146–155

 Drs Dean-Colomb and Esteva have no relevant relationships with commercial interests to disclose.

PII: S0093-7754(08)00043-2

doi: 10.1053/j.seminoncol.2008.02.008

Seminars in Oncology
Volume 35 , Pages S31-S38 , April 2008

Article Tools

* Image Usage & Resolution